

Raphaël Marlu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4053306/publications.pdf>

Version: 2024-02-01

35
papers

1,017
citations

687363

13
h-index

454955

30
g-index

37
all docs

37
docs citations

37
times ranked

1250
citing authors

#	ARTICLE	IF	CITATIONS
1	Acquired von Willebrand syndrome secondary to lymphoproliferative disorders: A case series from two French centers. <i>Thrombosis Research</i> , 2022, 209, 1-4.	1.7	1
2	Comparison of three modalities of plasmapheresis on coagulation: Centrifugal, singleâ€membrane filtration, and doubleâ€filtration plasmapheresis. <i>Journal of Clinical Apheresis</i> , 2021, 36, 408-419.	1.3	6
3	Apheresis Efficacy and Tolerance in the Setting of HLA-Incompatible Kidney Transplantation. <i>Journal of Clinical Medicine</i> , 2021, 10, 1316.	2.4	16
4	Fibrinogen reconstitution after therapeutic apheresis: Comparison of doubleâ€filtration plasmapheresis, plasma exchange, and immunoadsorption. <i>Journal of Clinical Apheresis</i> , 2021, 36, 574-583.	1.3	4
5	How to improve clotting factors depletion in doubleâ€filtration plasmapheresis. <i>Journal of Clinical Apheresis</i> , 2021, 36, 766-774.	1.3	1
6	Cerebral Venous Thrombosis: Clinical, Radiological, Biological, and Etiological Characteristics of a French Prospective Cohort (FPCCVT)â€™Comparison With ISCVT Cohort. <i>Frontiers in Neurology</i> , 2021, 12, 753110.	2.4	10
7	Effect of immunoadsorption alone or combined with membrane filtration on hemostasis parameters. <i>Journal of Clinical Apheresis</i> , 2020, 35, 444-452.	1.3	5
8	Factor VIII and IX assays for postâ€infusion monitoring in hemophilia patients: Guidelines from the French BIMHO group (GFHT). <i>European Journal of Haematology</i> , 2020, 105, 103-115.	2.2	5
9	Multicentre evaluation of <sc>CK</sc> Prest^Â for assaying plasma levels of factor IX fused with albumin (Idelvion^Â). <i>Haemophilia</i> , 2019, 25, e327-e330.	2.1	5
10	Splenic infarction associated with transient anti-prothrombin antibodies is a rare manifestation of acute <i>Mycoplasma pneumoniae</i> infection. <i>Archives De Pediatrie</i> , 2019, 26, 483-486.	1.0	8
11	Fibrinography: A Multiwavelength Lightâ€Scattering Assay of Fibrin Structure. <i>HemaSphere</i> , 2019, 3, e166.	2.7	7
12	Comparison of the ecarin chromogenic assay and diluted thrombin time for quantification of dabigatran concentrations: comment. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 1017-1019.	3.8	0
13	Impact of four direct oral anticoagulants on rotational thromboelastometry (ROTEM). <i>International Journal of Laboratory Hematology</i> , 2018, 40, 84-93.	1.3	59
14	Plasminogen gene mutation with normal C1 inhibitor hereditary angioedema: Three additional French families. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 2237-2239.	5.7	40
15	Reducing Fibrinogen and Factor XIII Using Double-Filtration Plasmapheresis for Antibody-Mediated Rejection: Predictive Models. <i>Blood Purification</i> , 2018, 46, 239-245.	1.8	9
16	Effect of double-filtration plasmapheresis for antibody-mediated rejection on hemostasis parameters and thrombin generation. <i>Thrombosis Research</i> , 2018, 166, 113-121.	1.7	16
17	Lethal cerebral hemorrhage after ticagrelor intoxication: a specific antidote is urgently needed. <i>Clinical Toxicology</i> , 2018, 56, 1200-1203.	1.9	9
18	Management of Severe Bleeding in Patients Treated with Direct Oral Anticoagulants. <i>Anesthesiology</i> , 2017, 127, 111-120.	2.5	52

#	ARTICLE	IF	CITATIONS
19	Normal PAI-2 level in French FXII-HAE patients. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1719-1720.	2.9	5
20	Catalytically inactive Gla-domainless factor Xa binds to TFPI and restores <i>ex vivo</i> coagulation in hemophilia plasma. <i>Haematologica</i> , 2017, 102, e483-e485.	3.5	9
21	Evaluation of dabigatran, rivaroxaban and apixaban target-specific assays in a multicenter French study. <i>Thrombosis Research</i> , 2017, 158, 126-133.	1.7	26
22	[PP.28.27] IS THAT OBSTRUCTIVE SLEEP APNEA PARTICIPATES IN THE DECREASE OF THE ANTIAGGREGANT EFFECT OF THE ASPIRIN OBSERVED IN PATIENTS WITH DIABETES MELLITUS. <i>Journal of Hypertension</i> , 2017, 35, e322-e323.	0.5	0
23	Questioning the use of an age-adjusted D-dimer threshold to exclude venous thromboembolism: analysis of individual patient data from two diagnostic studies: comment. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 2553-2554.	3.8	5
24	Managing Argatroban in Non-Obstructive Thrombosis of Mechanical Mitral Valve in Heparin Induced Thrombocytopenia Type II: A Case Report. <i>Journal of Clinical Case Reports</i> , 2016, 6, .	0.0	0
25	Large external quality assessment survey on thrombin generation with CAT: further evidence for the usefulness of normalisation with an external reference plasma. <i>Thrombosis Research</i> , 2015, 136, 125-130.	1.7	57
26	Ex vivo reversal of the anticoagulant effects of edoxaban – comments on the study by Halim et al.. <i>Thrombosis Research</i> , 2015, 135, 571.	1.7	0
27	Long-Term Therapy With Bevacizumab in a Patient With Glanzmann's Thrombasthenia and Recurrent Digestive Bleeding due to Gastrointestinal Angiodysplastic Lesions. <i>American Journal of Gastroenterology</i> , 2015, 110, 352-353.	0.4	11
28	Letter by Marlu et al Regarding Article, "Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects" • <i>Circulation</i> , 2012, 125, e615; author reply e616.	1.6	5
29	Gla-domainless factor Xa: molecular bait to bypass a blocked tenase complex. <i>Haematologica</i> , 2012, 97, 1165-1172.	3.5	8
30	Antithrombin-Independent Effects of Heparins on Fibrin Clot Nanostructure. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, 1320-1324.	2.4	32
31	Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban. <i>Thrombosis and Haemostasis</i> , 2012, 108, 217-224.	3.4	529
32	Optimal epitope composition after antigen screening using a live bacterial delivery vector. <i>Bioengineered Bugs</i> , 2010, 1, 51-60.	1.7	18
33	Optimization of a Type III Secretion System-Based <i>Pseudomonas aeruginosa</i> Live Vector for Antigen Delivery. <i>Vaccine Journal</i> , 2008, 15, 308-313.	3.1	24
34	High-Yield Production of Secreted Active Proteins by the <i>Pseudomonas aeruginosa</i> Type III Secretion System. <i>Applied and Environmental Microbiology</i> , 2008, 74, 3601-3604.	3.1	16
35	Adapting a conventional pcr assay for <i>Toxoplasma gondii</i> detection to real-time quantitative pcr including a competitive internal control. <i>Parasite</i> , 2007, 14, 149-154.	2.0	19